Emperor preserved trial: Empagliflozin effective to treat heart failure
The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic stable heart failure with preserved ejection fraction, irrespective of diabetes status.Incidence of Heart Failure in India appears to rise and estimates of prevalence range from 1.3 million to 4.6 million, with an annual incidence of 0.49–1.8 million....
The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic stable heart failure with preserved ejection fraction, irrespective of diabetes status.
Incidence of Heart Failure in India appears to rise and estimates of prevalence range from 1.3 million to 4.6 million, with an annual incidence of 0.49–1.8 million. Several drugs are being investigated to manage heart failure.
The safety and efficacy of empagliflozin in patients with symptomatic heart failure was assessed in 2997 Patients randomized in a 1:1 design to either empagliflozin 10 mg or matching placebo of 2,991 patients in the trial.
Health-related quality of life in patients treated with empagliflozin had significant improvement in patients with meaningful improvements was reported in American College of Cardiology journal. Most routinely used drugs for Heart failure with reduced ejection fraction have not shown to be effective among patients, however this drug marks the change of treatment options.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd